List of Antibodies Companies in China - 95

About 3S Pharmaceutical Group 3S Pharmaceutical Group is a leading bio-pharmaceutical company integrating R&D, production and sales, with a focus on improving the life quality of patients with high-quality medicines to benefit human health. At present, the Group owns more than 80 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Group owns 4 R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 25 kinds of products under R&D, 16 kinds of them are under R&D as the national first-class new drugs. The Group also owns 6 production bases complying with GMP standards. In the future, 3S Pharmaceutical Group will continue to uphold the concept of "Care for Life, Cherish Life, Create Life" to create a world's leading bio-pharmaceutical company in China.

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in preclinical stage used in the treatment of cancers; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of metastatic solid tumors. The company was founded in 2011 and is headquartered in Suzhou, China.

We are a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with our R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, we have built a global pipeline through collaborations and internal discovery with more than 10 drug candidates in development. We have assembled a world-class management team, built our unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation. We are committed to becoming an innovative biopharmaceutical company with global vision and strives to benefit patients worldwide. Our ultimate goal is to transform cancer into manageable conditions.

Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address global medical needs. Since our inception, we have established a distinctive and integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the fundamental components, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode. Akeso is actively developing a diverse pipeline of over 50 innovative assets in cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, and 13 pivotal/phase III trials ongoing. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug for the market. Additionally, the company has five other innovative bispecific antibody drugs in the clinical stage, including ivonescimab (PD-1/VEGF), PD-1/LAG-3, TIGIT/TGF-Beta, PD-1/CD73, and claudin18.2/CD47 bispecific antibodies.

Founded in 2023 and based in Shanghai, China, Allink Biotherapeutics is a biotech company dedicated to expediting the development of a diverse pipeline of FIC/BIC therapeutic candidates for oncology and immune diseases. Our goal is to harness our proprietary bispecific antibody and ADC technology platforms, along with efficient execution and business collaboration , to address critical unmet clinical needs.

Alphamab Oncology (Stock code: 9966.HK) is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment. With multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/ immunology, and we are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally.

Angel Pharmaceuticals was founded in 2020, focusing on develop, produce and sale of innovative oncology drugs. We develop four innovative drugs in China and build a platform for new drugs, aiming at the unmet medical needs of China's cancer drug market, and build China's first-class innovative drug company. Our management team has decades of clinical and drug research and development experience, which lays a solid foundation for the development of new drugs.

Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key unmet medical needs of serious musculoskeletal diseases. With the team’s experience and scientific expertise in new drug development, Angitia is dedicated to bringing innovative therapeutics to help patients in need.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of Treating Patients Beyond Borders. Since 2017, Antengene has built a pipeline of 9 oncology programs at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. We have successfully obtained marketing authorizations for selinexor, Antengene’s lead asset, in multiple Asia Pacific counties and regions including mainland China, Taiwan,China, South Korea, Singapore, and Australia.

四川百利天恒药业股份有限公司 百利药业是一家集研发、生产、营销为一体的现代化高新技术企业。拥有2个新药研发中心、1个抗体及ADC药物生产企业、1个化学中间体生产企业及1个化学原料药生产企业、2个化学。

Bio Bench co. ltd (www.bio-bench.com, Belgium and China) is aCRO (Contract Research Organization) that develops functionalantibodiesand bio-active proteins for drug discovery, in-vitro diagnostickits and biologicalresearch.

BioCity was established in December 2017. It is an innovative drug company created by local entrepreneurs who have a deep understanding of the Chinese pharmaceutical market and young returned scientists relying on the world's leading open drug innovation platform. The company is committed to the discovery, development and commercialization of novel or highly differentiated candidates (with no modality limitation) to treat diseases with significant unmet medical needs, particularly cancers and Nephropathy. Through internal research, open innovation platform and collaborations, BioCity has established a pipeline of more than 10 innovative programs including small molecules, monoclonal and bispecific antibodies as well as antibody-drug conjugate (ADCs).

Biomissile is a biopharmaceutical company that focuses on the drug development.

BioNova Pharmaceuticals Ltd is an innovative biotech company engaged primarily in the discovery, development and commercialization of breakthrough therapies for the treatment of diseases with high unmet medical need, with a focus on the Greater China market Our talent, scientific knowledge and research capabilities help us accelerate drug development in China and bring innovative medicines to the Chinese patients

BioRay is a commercial-stage biopharmaceutical company with a full suite of end-to-end capabilities in China. We focus on discovering, developing, manufacturing and commercializing medicines for immune-mediated diseases. Leveraging our expertise in immunology and diverse portfolio covering different therapeutic targets and cellular pathways, we are committed to delivering life-changing medicines and other treatment solutions for patients living with autoimmune diseases and cancer. BioRay has full-spectrum R&D expertise from drug discovery to late-stage development, industry-leading commercial-scale manufacturing and quality management systems, and a robust pipeline with more than 20 preclinical candidates and over 10 ongoing clinical projects. In addition, our well-established nationwide commercial operations support four marketed products in mainland China. Currently, we operate four R&D and manufacturing centers in Taizhou, Hangzhou and Shanghai, China and San Diego, US, and have over 1,300 employees worldwide dedicated to building a pre-eminent biopharmaceutical company by offering medicines of the highest quality while pushing the boundaries of scientific discovery.

Biosion is a global R&D biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived technologies including the H³ antibody discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific platforms. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase 1 clinical trials for atopic dermatitis and severe asthma. Biosion and partners have plans to progress additional assets into the clinic for oncology indications over the next year. Biosion has operations in the US, Australia, and China.

Bio-Thera Solutions is a clinical-stage pharmaceutical company focused on biologic therapeutics. Bio-Thera is developing a pipeline on innovative enhanced monoclonal antibodies and antibody-drug conjugates for the treatment of a broad range of cancers and other diseases as well as a pipeline of biosimilars in the autoimmune and oncology therapeutic areas. The company is headquartered in Guangzhou, China.

Biotheus (普米斯生物技术) aims to discover and develop effective therapeutic biologics for patients with cancer and inflammatory disease. We believe in creative scientific and industrial/academic collaborations in order to reach this common goal.

Our company was Founded in 2007, Minnesota Bioworld Biotech., a company (Bioworld) is a private enterprise. We are committed to providing customers with innovative research tools, used to help determine the mechanisms of cell function and disease. Company since its establishment, has become the Bioworld antibody of cellular signal transduction pathways of the world's leading manufacturers. We are the world research, diagnosis and treatment to provide quality products, to contribute the biological world.

Bliss Biopharmaceutical (Hangzhou) Co., Ltd. is a clinical-stage biotech company dedicated to the discovery, development, and commercialization of anti-tumor biotherapeutics. With the core value of 'Together, We Improve Human Health,' the company focuses on multi-level collaborations and developments to advance its mission.

Brise Pharma is a clinical stage biopharmaceutical company with a major focus on the development of innovative and highly differentiated treatments for chronic pain.

CANbridge Pharmaceuticals is a pharmaceutical company that focuses on developing and commercializing innovative medicines to address unmet medical needs.

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

who are we : Chempartner is an innovative company adhering to the principle of "Science First, Technology Leads," providing integrated services for pharmaceutical research and production (CRO+CDMO). It has developed advanced technological capabilities, assembled top-tier scientists, and equipped itself with state-of-the-art research, animal testing, and pharmaceutical intermediate production facilities. Vision Statement： We strive to ensure that all drugs can be produced and every disease can be addressed by creating an open-access platform equipped with the most advanced capabilities and technologies in the global pharmaceutical sector. Mission Statement Our goal is to revolutionize and expedite the discovery, development, and manufacturing of pharmaceuticals. By providing a comprehensive open-access platform, we empower our global healthcare partners and improve patient outcomes around the world. Our PROUD Culture Passion: Committed to customer satisfaction, continuous innovation, and a vibrant, energetic workplace. Responsibility: Embracing accountability, handling challenging tasks with integrity, and contributing to the community. Open Culture: Promoting teamwork, diversity, inclusion, and transparent communication. R&D Focus: Prioritizing research and development, advancing scientific excellence, and fostering innovation.

Convalife Pharmaceuticals is an innovative pharmaceutical company that specializes in drug research and development for tumor diseases. They are dedicated to developing innovative drugs and focus on antibody biopharmaceuticals and small molecule treatments.

CStone (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received ten NDA approvals for four drugs. Multiple late-stage drug candidates are now under pivotal clinical trials or registration. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

About DualityBio DualityBio is a clinical-stage company focusing on the discovery and development of the next generation ADC therapeutics for patients with cancer and autoimmune diseases. DualityBio has successfully established a number of next generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. Building upon deep understanding of disease biology and translational capability, DualityBio has advanced 4 assets into global clinical studies, and developed more than 10 innovative product candidates which are currently in preclinical stage. Additionally, DualityBio is continuing evolving its novel protein engineering and ADC technology platforms for the next wave of “super ADC” molecules including diverse payload classes, bispecific ADCs and dual payload ADCs. For more information, please visit www.dualitybiologics.com. 关于映恩生物 映恩生物（Duality Biologics）是一家临床阶段的创新生物药企，专注于为全球癌症患者和自身免疫性疾病患者研发新一代 ADC 疗法。映恩生物已成功构建了多个具有全球知识产权的新一代抗体偶联药物（ADC）技术平台。基于对疾病生物学机制的深入研究和探索，映恩生物已经拥有四项临床管线与十多项临床前创新项目并持续改进其新型蛋白工程和ADC技术平台，以开发下一代“超级ADC”分子，包括全新作用机制载荷、双特异性ADC和双有效载荷ADC。映恩生物已与海内外多个跨国药企达成多项重磅授权合作，并在全球开展多个国际多中心（MRCT）关键性临床研究。致力于成为世界领先的ADC公司。 如需更多信息，请访问www.dualitybiologics.com

Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. A pipeline of novel molecules has been developed using its proprietary platforms including a powerful Bispecific Macrophage Engager (BiME®) technology that connects and activates macrophages for solid tumor killing without causing cytokine storms.

Eluminex Biosciences is a clinical-stage biotechnology company focused on development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of ophthalmic diseases.

EpimAb Biotherapeutics, Inc., is a China-based, privately held, start-up company founded in 2015 that is developing a portfolio of novel bi-specific antibodies in oncology and immune-oncology. All bispecifics are based on a proprietary platform, FIT-Ig (Fabs in Tandem). Multiple FIT-Igs have already been successfully generated binding to small, large, soluble or membrane-bound antigens with biochemical and biophysical properties similar to their parent monospecific antibodies. The first molecule, EMB-01, is a cMET/EGFR-inhibitor, that is in CMC development in collaboration with WuXi Apptec. EpimAb also has concluded licensing arrangements, e.g. with Kymab and Innovent Biologics, and is open to further partnerships.

Sinovent is a global biopharmaceutical company focused on discovery, development, and commercialization of innovative therapeutics for the treatment of cancer and autoimmune diseases.

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business. Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products. Fosun Pharma’s innovative products mainly covered core therapeutic areas such as tumors (solid tumors and hematologic tumors), immunology, central nervous system, and chronic diseases (liver disease/metabolism/kidney disease). Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “Innovation Transformation, Integrated Operation and Steady Growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets.

Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Europe and China.

GeneQuantum, headquartered in China, is a global leader in the ADC field, distinguished for its advancement of enzymatic site-specific conjugation technologies. Our pioneering technologies, iLDC and iGDC, serve as the foundation of our comprehensive ADC drug development platform, spanning from the initial design to seamless commercial production. The technology offered by GQ provides numerous advantages, such as exceptional product homogeneity, elevated process quality, and enhanced metabolic stability. Our continuous conjugation process seamlessly integrates with standard antibody production, ensuring the efficient creation of high-quality ADC drugs that rival the efficiency of antibody drugs. GQ's integrated approach leads to a substantial reduction in commercial production costs for ADCs. GQ remains steadfast in its commitment to delivering vital technical support, expediting global ADC drug development. Our dedication to collaborative synergy underpins mutual growth and success across diverse domains of ADC development.

GeneQuantum, headquartered in China, is a global leader in the ADC field, distinguished for its advancement of enzymatic site-specific conjugation technologies. Our pioneering technologies, iLDC and iGDC, serve as the foundation of our comprehensive ADC drug development platform, spanning from the initial design to seamless commercial production. The technology offered by GQ provides numerous advantages, such as exceptional product homogeneity, elevated process quality, and enhanced metabolic stability. Our continuous conjugation process seamlessly integrates with standard antibody production, ensuring the efficient creation of high-quality ADC drugs that rival the efficiency of antibody drugs. GQ's integrated approach leads to a substantial reduction in commercial production costs for ADCs. GQ remains steadfast in its commitment to delivering vital technical support, expediting global ADC drug development. Our dedication to collaborative synergy underpins mutual growth and success across diverse domains of ADC development.

Founded in 2007, Genor Biopharma Co. Ltd (Genor BioPharma, Stock code: 6998.HK) is an innovation-driven biopharma company with a pipeline of therapies covering the world's top oncology areas (breast, lung, and gastrointestinal cancer).

Gensciences, also known as Shengsi Biopharma, is an innovative biopharmaceutical company based in Nantong, China. The company is privately held and has received venture capital backing. Gensciences is dedicated to improving the lives of people living with hemophilia and has received hundreds of millions of yuan in Series D financing. The company's innovative development strategy focuses on drug pipelines, patents, and clinical trials for hemic and lymphatic diseases. For more information, you can visit their official website at http://shengsi.haio.cn/index.html.

loria Biosciences (誉衡生物) is a commercial stage biopharma company founded in 2016, bringing together a seasoned development and management team with global versions, and dedications to developing patient-centered treatments. In 2021, Gloria Bio has successfully launched and commercialized a novel, fully human anti-PD-1 mAb, zimberelimab ("Yutuo", "誉拓”), for the treatment of relapsed or refractory classical Hodgkin’s lymphoma, which demonstrated an overall response rate (ORR) of 92.86%, DCR of 96.43%, and 12 month overall survival rate of 99% with improved long-term survival benefits for patients. Zimberelimab is also designated as Breakthrough Therapy by China's Center for Drug Evaluation for the treatment of recurrent or metastatic cervical cancer, which has been approved in July 2023, marking the first and only PD-1 mAb approved in China for cervical cancer, and third globally. Currently, zimberelimab is being evaluated in multiple types of cancer, including prostate, colorectal, non-small cell lung, pancreatic, triple-negative breast, head and neck, and renal cell cancers, etc. It is also being studied in combinations with multiple innovative drugs, targeting CD47, CD73, TIGIT, A2aR, CCR8, LAG-3, CD40, CD39, Trop-2, CAR-T, HER-2 ACD and Neo-T, etc. Gloria Biosciences is striving to build a pipeline with more effective treatment alternative for cancer patients, including LAG-3 and other innovative monoclonal and biospecific antibodies.

Gmax Biopharm LLC. has built up an in-house antibody development platform which enables the antibody screening, humanization, and engineering, in order to obtain the GPCR antibody therapeutics for unmet medical needs in cardiovascular diseases, metabolic disorders, and cancer. The company is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) and has developed the world's first ETa-specific monoclonal antibody. Gmax Biopharm has also partnered with Sino Biopharmaceutical Ltd. and has a strong pipeline of products in development.

Xiangxue Life Sciences (XLifeSc) is a biopharmaceutical company focused on TCR-based therapies for cancer. Our main proprietary technological platforms are composed of: (1) High Affinity T Cell Activation Core (HATac) ; (2) TCR Affinity Enhancing Specific T Cell Therapy (TAEST) . The two platforms have been fully developed to the clinic-ready stage. As a result, an independently-owned intellectual property portfolio has been constructed which spans across the whole spectrum of TCR-related technologies including the identification of tumor-specific antigens, antigen-specific TCRs, and the optimization of antigen-specific TCRs in terms of affinity and stability, etc. To date, many domestic and PCT applications have been filed. Housing several state-of-the-art laboratories, XLifeSc is capable of offering a broad range of R&D services, including (1) large scale GMP grade lentivirus production; (2) target identification and lead optimization; (3) efficacy validation and safety testing in cell lines and animal models; (4) clinical trial development; and (5) market entry planning. These capabilities and services can be either accessed as flexible stand-alone services on demand or as a part of integrated drug discovery programs. To meet the needs of different partners, we welcome all types of alliance opportunities such as out-license, co-development, and co-marketing.

Founded in 1992 and listed in 2015, Wondfo is a fast-growing biotechnology company in China. Wondfo mainly focuses on rapid diagnostics in China but is looking for further development in other areas of the healthcare industry. Besides the headquarter in Guangzhou, Wondfo also owns 2 overseas labs, 1 branch in Chicago, and 11 overseas offices. After many years’ efforts in delivering high-quality products and services, Wondfo has won a good reputation around the world. In production, Wondfo strictly complies with national and international regulations and standards. We have got CE certificates, FDA certificates, FSC certificates, ISO 9001:2008, and ISO 13485:2012 quality system certification. Wondfo attaches great importance to research and development and sees innovation as the soul of the enterprise’s development. So far, Wondfo has 530+ highly-qualified researchers and over 30% of the staff have obtained master's and doctorate degrees from prestigious universities worldwide. Wondfo also has built R&D laboratories in Guangzhou and San Diego. With our advanced production lines and highly experienced staff, Wondfo’s daily production capacity of test kits reaches 1.5 million. Wondfo also provides a number of customized services to professional distributors and partnering affiliates. Wondfo provides high-quality products at a very competitive price, together with professional technical support and counseling service. Currently, Wondfo has customers in more than 120 countries and areas. It is our commitment to safeguarding the health and improving lives with better products, services, and solutions. With more than 3000 dedicated employees, we'll continue to innovate and shape the future of POCT and healthcare.

Established in 1998 in Shenzhen, China, Hepalink is a leading multinational biopharmaceutical company dual-listed in Hong Kong and mainland China, with its core business in heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs. These three synergistic business segments are driven by the mission of addressing patients' unmet medical needs and bringing safe and effective therapies and services to patients around the world.

Clinical stage immuno-oncology company focused on novel applications of liposome constructs to disrupt existing immuno-oncology technologies. The company's lead clinical development program is HF1K16, a drug encapsulated immune modulating liposome of all-trans retinoic acid targeting myeloid-derived suppressor cells for treatment of solid tumor cancers. Additional programs include immunoliposomes designed to improve efficacy and toxicity of existing of existing immuno-oncology technologies including ADCs and CAR-T.

Himalaya is a clinical stage, therapeutic company focused on developing innovative, differentiated therapies in greater china and worldwide. The company has exclusive rights to deploy CAB antibodies in its territories, with the goal of delivering safer, more potent cancer therapies to patients timely and cost effectively.

Hope Medicine (HopeMed) is a science-driven, patient-centric, clinical-stage biotech company with research and development bases in major innovation hubs in China. The company was established on the foundation of deep understanding of disease biology and translational medicine, and decades of scientific research in the laboratory of the founder, Professor Rui-Ping Xiao, at Peking University. With a management team of highly accomplished industry veterans combining entrepreneurship and global pharma experience, HopeMed is committed to the discovery, development, and commercialization of innovative, safe, effective, affordable medicines for large, underserved patient populations. Strategically, we are building a robust pipeline in the field of endocrine, cardiovascular and metabolic diseases, with a special focus on women’s health, through internal R&D capabilities, access to external technology platforms to enable a variety of molecular modalities, as well as in-license of complementary and differentiated assets to address unmet medical needs.

Shenzhen Huixin Biomedical Technology Co., Ltd. (hereinafter referred to as Huixin Bio) is a national high-tech enterprise co-founded by well-known scientists and industry experts in the field of exosomes. It is committed to promoting the research and application of exosomes in the field of early diagnosis and treatment of cancer, developing world-leading biomedical technologies, meeting urgent clinical needs, and continuously improving the automation and intelligence of products to overcome key bottleneck technologies in the field of exosome diagnosis and treatment. Huixin Bio was shortlisted for the national industry finals of the China Innovation and Entrepreneurship Competition in 2019, won the third prize of the "Startup Star Competition" in the biopharmaceutical industry, won the small and micro intellectual property advantage enterprise in Longhua District, Shenzhen in 2020, and passed the national high-tech enterprise certification in 2022.

IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput CAR-T drug priority platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This includes a diversified portfolio of 8 novel pipeline products, as well as IASO’s leading asset, CT103A, an innovative anti-BCMA CAR-T cell therapy under pivotal study for relapsed/refractory (R/R) multiple myeloma (RRMM), which was granted Breakthrough Therapeutic Designation by China’s National Medical Products Administration (NMPA) in February 2021. In addition. The company’s in-house developed fully human CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy, has received two IND clearances from NMPA for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in July 2021.

ICE Bioscience was founded in 2010 as an Innovative CRO+ Explorer company. We specialize in early drug discovery services, spanning from target validation to the identification of pre-clinical candidates. Currently, ICE Bioscience offers a broad selection of off-the-shelf assays, including 100+ ion channels, 800+ Kinases/enzymes, 100+ GPCRs, and 40+ nuclear receptor assays, all accompanied by validation data and screening information. This comprehensive range of assays provides us with a competitive edge, as it covers a vast majority of druggable targets. Our company has established multiple platforms, encompassing Protein Engineering, Cell Line Development, Target Based Assays, Safety Pharmacology, Translational Biology, DMPK, In Vivo Pharmacology and Biophysical Assays, enabling us to smoothly execute the DMTA cycle (Design-Make-Test-Analysis cycle) for innovative drug discovery in collaboration with our clients.

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. It is developing Felzartamab (TJ202), a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin (TJ101), a long-acting human growth hormone that has completed Phase II clinical trials to treat pediatric growth hormone deficiency; and Olamkicept (TJ301), a IL-6 blocker, which is in Phase II clinical trials for the treatment of ulcerative colitis and autoimmune diseases. The company’s product candidates also include Enoblituzumab, a humanized B7-H3 antibody that has completed Phase I clinical trials to treat head and neck cancer and other oncology diseases; Efineptakin (TJ107), a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme (GBM) patients with lymphopenia; and Plonmarlimab (TJM2), a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies. In Addition, it is developing Lemzoparlimab (TJC4), a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Uliledlimab (TJD5), a CD73 antibody, which is in Phase I clinical trials for treating solid tumors and oncology. Its product candidates in pre-clinical development comprise TJ210, a monoclonal antibody against human C5aR1 for the treatment of cancers and potentially autoimmune diseases; TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM and TJ-CLDN4B antibodies for treating oncology diseases. I-Mab has a strategic collaboration agreement with AbbVie Ireland Unlimited Company to develop and commercialize Lemzoparlimab. The company was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.

ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd., founded in June 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an clinical-stage biopharmaceutical company dedicated to development and commercialization of novel cancer immunotherapeutics that reverse cancer cell-induced immune inhibition and actively eradicate cancer cells. To achieve these goals, we have established several proprietary platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells, to fulfill the cancer-killing tasks. Macrophages play critical roles in fighting cancer through phagocytosis followed by tumor antigen presentation to T cells, which in turn destroy antigen-expressing tumor cells. However, cancer cells have evolved to evade immune surveillance, by mechanisms such as over-expressing CD47 and inhibiting phagocytosis via interaction with signal regulatory protein (SIRPα) on macrophages. We are developing a pipeline of compounds for reversing cancer cell-induced inhibition of innate immunity. NK cells are innate defense mechanisms of the body against viral infection and cancer, which directly target pathogenic cells without requirement for MHC recognition. We have established proprietary platforms and target-activated NK (TANK™) cell therapy for treatment of both leukemia and solid tumors. ImmuneOnco is actively advancing pipelines of proprietary platform-based compounds targeting a broad range of canncer indications.

The company is focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody Immuno Blocking technology platforms; with 2 vaccines in first-in-human clinical trials.

InnoCare Pharma is a commercial stage biopharmaceutical company dedicated to discovering, developing, and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. InnoCare has strong in-house innovation capabilities, holding multiple foreign and domestic patents with a rich product pipeline target liquid tumors, solid tumors, and autoimmune diseases. Our team has discovered and developed a strong pipeline. InnoCare was co-founded by Professor Shi Yigong, a world-renowned structural biologist, and Dr. Cui Jisong, an outstanding leader in the biopharmaceutical industry. We have over 1000 employees. Our core R&D staff brings rich experience from the world's top pharmaceutical companies, such as Pfizer, GSK, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer, etc. We are a truly global biopharmaceutical company with sites in Beijing, Nanjing, Shanghai, and Guangzhou, Hong Kong and Unites States. On March 23, 2020, InnoCare officially listed on the Hong Kong Stock Exchange (code: 9969). And on Sept. 21, 2023, InnoCare successfully got listed on STAR Board of Shanghai Stock Exchange (code: 688428). Our vision is to become a world-class biopharma leader to address the unmet medical needs globally.

北京因诺惟康医药科技有限公司（Innovec Biotherapeutics）是一家从事基因治疗技术和产品研发的公司，成立于2020年8月，位于北京生命科学园，公司创始人为多位留美归国的生物医药专业的博士，有着丰富的病毒学、基因治疗研发和生产、临床医学等方面的经验。公司于2021年6月完成数千万天使轮融资。参与天使轮投资的基金主要是具有丰富医药行业投资经验的知名的创投基金和投资人。 因诺惟康目前有诸多基因治疗的产品管线储备，大部分集中于眼科和神经科领域，公司生物医药技术包括新型病毒载体的设计和开发、基因编辑药物开发，临床级病毒载体的生产和应用，研究遗传疾病的自然发生过程、特征及突变基因，建立遗传疾病相关的动物模型。公司主要项目处于临床前的研究阶段。

Established in 2018, InxMed strives to be a China-based global new drug development engine dedicated to the development of innovative drugs with high probability of success and meaningful value for patients globally by execution of our “Best-in-Disease Combination” strategy and leveraging China clinical resources. In InxMed, we think differently, because we know the deep understanding of disease biology and value-driven study design are how we differentiate from others. In InxMed, we value the highest efficiency in execution and expeditious generation of “PoC” data, because we know “Vision without execution is hallucination”. In InxMed, we believe combination therapy is the future for oncology, and triple or multiple drug combinations are emerging with great potential. In InxMed, we strive to build up a pipeline consisting of “First-in-Class” and “Best-in-Disease Combination” assets, driven by intrinsic potential of synergy.

Founded in 2018, Jianda Biopharmaceuticals (Nanjing) Co., Ltd. is a biopharmaceutical company founded by domestic and foreign vaccine research and development, industrialization and commercialization experts and an elite team in the pharmaceutical industry. Its headquarters is located in the Biopharmaceutical Valley of Nanjing Jiangbei New District. Driven by independent innovative technologies, Jianda Biopharma focuses on the development and industrialization of new human vaccines and biopharmaceutical products such as tumor treatment. Since its establishment, the company has devoted itself to research and development and established a DC-targeted VLP vaccine technology platform and a circular mRNA vaccine technology platform with independent intellectual property rights. A series of innovative products based on platform technologies are in the POC, pilot production and pre-IND stages. In 2021, the company completed its angel round of financing, with Shenzhen Songshan Capital and Dongguan Juying Capital investing 33 million yuan, pushing multiple of the company's products from R&D to pre-IND. The company focuses on the field of life and health, introduces company teams, insists on pioneering and innovation, deploys multiple product pipelines, and strives to bring new vaccines developed to the market to benefit human life and health.

科兴制药是一家主要从事重组蛋白药物和微生态制剂的研发、生产、销售一体化的创新型生物制药企业，专注于抗病毒、血液、肿瘤与免疫、退行性疾病等治疗领域的药物研发，并围绕上述治疗领域拥有一定中药及化学药技术沉淀。 科兴制药主要产品包括重组蛋白药物"重组人促红素"、"重组人干扰素α1b"、"重组人粒细胞刺激因子"，微生态制剂药物"酪酸梭菌二联活菌"。公司主要产品已沉淀一定行业优势地位和市场影响力，近年来依托政策支持和营销渠道深耕，保持稳定增长。

Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor and tumor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancers, alopecia and acne.

KMD Bioscience is a biotech company located in Tianjin, China. Our CRO services&products cover antibody engineering(recombinant antibodyproduction, antibody sequencing&purification), protein production, expressionand purification and other services related to phage display, stable cell lineconstructionand peptide.

Landwind Medical has been a professional medical equipment manufacturing company since 1994. With over 25 years of experience in the medical industry, today, Landwind has six R&D centers and four production lines around China, besides Shenzhen's headquarters. Also, Landwind has perceptive R&D teams of 300+ professionals with medical practice and product development backgrounds. Landwind Group has four subsidiaries manufacturing different categories of medical products: Landwind Bio: for in-vitro diagnostic equipment and reagent solutions; Joyheal: for hemodialysis solutions; Landsky: is a specialist in ventilator & anesthesia solutions; Landwind Health: for home care/medical solutions. Professionally, Landwind is accumulating, gaining many professional awards and certificates every year, among them the CE, ISO9001, and CMD certificates, besides hundreds of local awards, Medical Device Manufacturing certificates, and patents. Landwind's products and professional staff are always on the front line with medical companies in most medical exhalation and fairs early, aiming to expand its cooperation network and open new markets. Landwind Medical's distributing network exceeds 800 and has more than 120,000 active clients covering more than 150 countries.

Founded in 2019 in Shanghai, China, LaNova Medicines is a clinical-stage biotechnology company committed to the discovery and development of novel biologic drugs for cancer treatment. Led by industry veterans with a strong passion for innovation, we aim to operate as an R&D engine and deliver transformative medicines to address the unmet clinical needs of cancer patients. Leveraging our proprietary technology platforms and deep understanding of the tumor microenvironment. we have built a differentiated pipeline of products and are striving to progress our programs toward the clinic.

Leads Biolabs Nanjing Leads Biolabs Co., Ltd is a clinical-stage biotechnology company. Since 2014, the company has been operating in the development of single-target antibodies and bispecific antibody new drugs. It has also announced worldwide license and collaboration agreements for anti-LAG-3 antibody and received FDA approval for IND application for bispecific antibody. Leads Biolabs is also involved in the development and manufacturing of mAb candidates in collaboration with Chime Biologics and BeiGene.

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company focusing on oncology therapeutics with a strong China foundation and global vision. Our mission is to become a leading innovative company serving the unmet medical needs of cancer patients with first-in-class and best-in-class drugs. We strive to continuously develop a market differentiating pipeline by combining in-house research and development and strategic collaborations, strengthen in-house manufacturing, and commercialize our pipeline products through dedicated sales and marketing forces in China as well as via partnerships internationally.

LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. The company’s lead development program is with catumaxomab, a clinically validated bispecific antibody which was the first approved T-cell engager, and its associated Triomab technology platform. LintonPharm, in collaboration with Lindis Biotech, is also developing a next generation bispecific antibody platform known as Fleximab which aims to provide better CMC developability and less immunogenicity. The LintonPharm pipeline includes several treatments in development for blood cancer and solid tumors that use the Triomab and Fleximab platforms. For more information, please visit www.lintonpharm.com.

Shenzhen Liying Biotechnology Co., Ltd. is a synthetic biology company based on the foundation of structural biology and cutting-edge artificial intelligence computation. We specialize in protein design and modification, providing high-quality and efficient research and development services for various protein applications, as well as the synthesis of protein materials. The company’s core technology founders and team members have over a decade of experience studying in the UK, with deep expertise in protein structure and function cultivated at top international universities and research institutions such as the University of Oxford, the University of Cambridge, and the Francis Crick Institution. They possess comprehensive technical workflows for advanced protein performance optimization and design that is internationally recognized. We have assembled a scientific advisory team at the Nobel Prize and Royal Academy Fellow level, as well as experts of high caliber from both domestic and overseas talent pools. Additionally, they have established extensive connections in industry, policy, and resources through the Chinese Central Organization Department’s Thousand Talents Program.

Longbio Pharma is founded in 2018, and located in Zhangjiang Hi-tech Park, Shanghai. There are 40+ scientists, 10+years experiences in protein drug development (antibodies and fusion proteins) .The co-founder team successfully developed two drugs for marketing (accumulated global sales USD 30 Billion). Longbio Pharma is focusing on R&D the innovative drugs of autoimmune and rare diseases (allergy and complement).

Lyvgen is a biopharmaceutical company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs. Lyvgen’s most advanced programs include LVGN6051, a monoclonal antibody (mAb) agonist for CD137/4-1BB, LVGN7409, a mAb agonist for CD40, LVGN1673, a bispecific antibody (BsAb) blocking PD-L1 and trapping TGFβ1/2/3, and anti-PD-1 blocking antibody LVGN3616. Lyvgen has initiated Phase I clinical trial of LVGN6051 alone or in combination with anti-PD-1 antibody in the USA. Lyvgen plans to start Phase I testing of LVGN6051 in China, LVGN7409 and LVGN1673 globally. Lyvgen employs over 35 scientists with global pharmaceutical research and development experiences at its research sites in China and the USA.

Mab Works is committed to bringing novel therapeutics to patients and aspires to become a globally integrated biopharmaceutical company. Their mission is to translate innovative science into value for patients and shareholders.

Medilink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and the latest generation of technologies and products. Founded in 2020, the company is dedicated to developing globally competitive conjugated drugs with a focus on therapeutic effect.

Shanghai Miracogen is a biotechnology company that offers development, clinical research, and industrialization of new products for the treatment of various diseases such as breast cancer and non-small cell lung cancer. The company is a clinical stage biotech company fully owned by Lepu Biopharma.

Developer of biotechnology focused on biopharmaceuticals. The company's innovative biologic drug anti-HER2 is a new generation of monoclonal.

NOVOPROTEIN SCIENTIFIC , the mRNA reagent materials and recombinant proteins supplier from China. Novoprotein provides a one-stop solution of mRNA raw materials and services to support mRNA vaccines research and development. Our products include restriction enzymes, T7 RNA Polymerase, RNase inhibitor, Pyrophosphatase, DNaseI, Nucleotides, Vaccinia Capping Enzyme, mRNA 2´-O-Methyltransferase, Poly(A) Polymerase, RNase R, etc. The manufacturing processes are strictly controlled to ensure the products are animal-free and ampicillin-free. We guarantee the manufacturing and quality control comply with GMP regulation for tracking each step of the manufacturing process, including raw material sourcing. Novoprotein has developed more than ten thousand of recombinant proteins, like cytokines in cell therapy and organoid culture. We have researched and developed 7 technology platforms and 23 core technologies, including protein design and modification, protein production and quality control, protein application and evaluation. Novoprotein provides biomedical Industry customers with services from product development to technological innovation based on a comprehensive technology system and in-house innovative raw materials. James Pan - International Business Development email address: panyanzhi@novoprotein.com.cn

Founded in 2015, Oricell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy.

Overland Pharmaceuticals is a biopharmaceutical company founded in 2020, dedicated to developing innovative medicines for underserved patients in Asia and around the world. The company is supported by Hillhouse Capital and focuses on building a fully integrated biopharmaceutical platform through strategic collaborations in key disease areas. The company emphasizes advanced modalities, including in-house research and development and strategic partnerships. Overland Pharmaceuticals is particularly focused on creating an oncology portfolio that features first-in-class antibody-drug conjugates and allogeneic cell therapy programs, targeting the greater China and Asia markets through collaborations with established biotechnology firms. With international offices in Shanghai, Beijing, and Boston, Overland Pharmaceuticals leverages its strong network in Asia while engaging with global biotech innovation. The leadership team includes co-founders Hua Mu, MD, PhD, and Ed Zhang, MBA, both experienced executives in the life sciences sector. The company operates within a financially healthy range, indicating stability and growth potential in the biopharmaceutical industry.

Founded in 2020, Overland Pharmaceuticals is establishing a leading cross-border platform company focused on advanced modalities through strategic partnering and in-house R&D. Overland is seeded by Hillhouse Capital with access to global innovation and China biopharma ecosystem. Overland is building an initial oncology portfolio of first-in-class ADC and allogeneic cell therapy programs for greater China and Asia through partnering with established biotechs. Through formative R&D partnerships and in-house technology platforms, Overland will move forward the development and commercialization of the most promising advances in medicine.

Shenzhen Pregin Biopharmaceutical Co., Ltd. is a national high-tech enterprise, Guangdong Provincial Cell and Gene Therapy Innovative Drug Engineering Technology Research Center, and Shenzhen Special New Enterprise. Investor shareholders include the National Small and Medium Enterprises Development Fund and the National Science and Technology Commission of the Chinese Academy of Sciences. Jiahe Fund, Haier Capital, Shenzhen Capital Group, Winbond Health ( 002004), etc. It has been deeply involved in the field of cell and gene therapy drugs for many years.

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain, and has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS”, to accomplish the mission “to make the R&D easy for innovative biologics”.

SciNeuro Pharmaceuticals is an innovation-driven, neuroscience-focused biopharmaceutical company with an established pipeline of novel therapeutic candidates to address neurodegenerative and other CNS diseases. The company focuses on targets that are supported by human biology and which play a critical role in regulating foundation biology, to achieve better probability of success in clinical development. SciNeuro is committed to delivering medicines that can make a difference to improve the lives of patients around the world, transforming scientific discoveries into groundbreaking therapies.

Shanghai Henlius Biotech isabiopharmaceutical company in China that is developing biologics foroncology and autoimmune diseases.

Junshi BioPharma is an innovation-driven biopharmaceutical company which is dedicated to the discovery and development of innovative drugs and their clinical research and commercialization on a global scale. Our mission is to provide patients with treatment options that work better and cost less. Based on the core platform technology of protein engineering, Junshi stands at the frontier of R&D of macromolecular drugs. With distinguished capability of innovative drug discovery, advanced biotechnological R&D, large-scale production capacity on the full industry chain and rapidly expanding drug candidate portfolio of tremendous market potential, Junshi has a leading edge in the PRC in the emerging field of immuno-oncology and for the treatment of autoimmune and metabolic diseases. Junshi is the first PRC company filing IND application and NDA application to the NMPA for anti-PD-1 monoclonal antibody, and also the first PRC company to receive IND approvals from the NMPA for anti-PCSK9 monoclonal antibody and anti-BLyS monoclonal antibody. Our vision is to become a pioneer in the area of translational medicine by developing first-in-class and best-in-class drugs through original innovation. With enrichment of our product pipelines and exploration of drug combination therapies, Junshi expanded its innovation to the R&D of more types of drugs, including small molecule drugs and antibody drug conjugates (or ADCs), as well as to the exploration of the next-generation innovative therapies for cancer and autoimmune diseases.

Shenogen Pharma Group is a drug discovery and development company founded in 2006 at Beijing, China. Shenogen aims to develop and commercialize first-in-class therapeutics for cancer and autoimmune diseases. Our first and leading compound Icaritin is an excellent example of Shen Nong meeting Gene, as Icaritin is isolated from a traditional Chinese herb, and is currently being examined as a First-in-Class drug candidate in phase III clinical trial to treat liver cancer. Utilizing modern biotech platforms, novel targets and independent intellectual properties, we have successfully generated a rich research portfolio beyond Chinese herbs. Our new drug candidates ranging from small molecules, oncolytic viruses, to various forms of antibody based biologics, are being developed in stages from discovery to late clinical trials. Currently, we are establishing a full pharma value chain from research to production and commercialization. Our subsidiary companies focusing in different segments of the value chain are set up indifferent places in China including Beijing, Shandong, Hubei, Hunan, and Guangzhou. We are dedicated to bring our R&D innovations to the patients, and to providing them and their families with better health and better lives.

海思科医药集团成立于2000年，是一家以新药研发为核心，销售能力特别突出的医药类集团化上市公司。集团是肠外营养行业领导者，在肝病领域细分市场占据重要地位，是全国排名前列的肝病用药生产销售基地，现有员工超过1900名。 公司自2012年1月17日在深圳证券交易所A股上市以来，在资本市场有着良好的表现，目前股票市值约270亿人民币，A股排名前380、中小板排名前59、全国医药上市公司中长期排名25、化学药子行业上市公司排名第7 位、上市公司市值管理绩效百佳榜第9位、中国上市公司市值管理绩效百佳、中国医药行业最具影响力榜单成长50强企业、2014福布斯中国上市潜力企业100强位列第三位、医药类企业第一位、2015福布斯中国潜力企业。 公司坚持以新产品研发作为企业发展的核心驱动力，经过多年积累与实践，公司已建立450人的研发团队，其中包括50余名博士、近百名硕士，95%以上成员具有药学或相关专业本科以上学历，公司研发团队技术水平、团队人数在国内医药企业处于领先水平，公司首仿成功率行业第一，近五年新药批件取得数量全国第三。 公司于2015年正式进军高端医疗器械市场。

SinoMab BioScience Limited (stock code: 3681.HK) is a Hong Kong based clinical-phase biopharmaceutical company focus on the development of novel and high-value recombinant therapeutic proteins for treating various life-threatening and debilitating diseases in human.

An Unique TIDEs Platform with Cutting Edge Technologies As an industry leader in therapeutic peptides, Sinopep stands as the exclusive API supplier for Albuvirtide and Lanreotide 505b2—two of the top five in-demand peptide products. We are also the global leader in supplying Semaglutide, Tirzepatide, and Liraglutide, dominating the market in export quantity. Sinopep consistently delivers the highest quality peptide APIs, supported by comprehensive documentation that meets stringent global standards. Our advanced process development and manufacturing technologies ensure efficient production with high yields and some of the largest batch sizes in the industry. Additionally, Sinopep excels in providing efficient, flexible, and high-quality end-to-end CRDMO services across multiple modalities, including peptides, oligonucleotides, small molecules, and related synthetic conjugates. This makes Sinopep a trusted partner in the pharmaceutical and healthcare industries worldwide.

SmartNuclide Biopharma is a biopharmaceutical company that focuses on discovering and developing innovative biologics used in nuclear medicine, with a world-leading research and development technology platform for domain antibody-radiopharmaceuticals.

Shuoxing Biotech is a biopharmaceutical company committed to the development of efficient and low-toxic multifunctional antibody medicines. Shuoxing Biotech is a biotechnology company based in China that has raised an undisclosed amount of money in funding.

Starna Therapeutics focuses on extrahepatic targeted delivery technology and is committed to developing innovative drugs with RNA as the core to solve unmet clinical needs. The core team comes from well-known pharmaceutical companies, universities and research institutes. The team has profound capabilities in nucleic acid drug discovery, delivery technology and formulation development.

TransGen Biotech Co., Ltd is a researcher and manufacturer of molecular and cellular biology products.

VivaChek is a leading in-vitro diagnostics company dedicated to enhancing the quality of life by delivering precise and swift disease diagnoses. Our commitment lies in the advancement of healthcare through ongoing research and development in blood glucose monitoring systems, Hemoglobin & Lipid Testing System, FIA Testing System, lateral flow rapid test and Molecular Diagnostics. Our expertise encompasses the development, manufacturing, and distribution of top-tier biosensors and Point-of-Care Testing (POCT) products. Our biosensor offerings span a range of critical parameters, encompassing blood glucose monitoring systems, lactate analyzers, blood ketone meters, and uric acid analyzers. In addition to biosensors, our comprehensive POCT product portfolio includes state-of-the-art PCR, immunoassay, and biochemistry solutions. With a focus on precision, efficiency, and accuracy, our POCT products cater to diverse medical needs, contributing to the rapid and reliable diagnosis of various health conditions.

亿帆医药股份有限公司是一家在深圳交易所A股上市的企业，证券简称：亿帆医药，证券代码：002019。 公司为医药创新型研发生产企业，设有亿帆研究院、国家级博士后科研工作站、省级企业技术中心（研发中心），旗下拥有多家高新技术企业，现有药学及相关专业硕士、博士逾百名，拥有双分子技术、免疫抗体技术两大先进生物药创新研发平台，已获国际及国内药品相关专利授权近百项，其中国际专利35项。 公司承担了国家"十五"攻关项目、国家高技术产业化示范工程项目、国家火炬计划项目等，曾荣获国家发明二等奖、国家科技进步二等奖各一项。 公司以专业性、专科性及治疗型重点专科领域产品线为导向，不断创新，转型升级，向大分子生物药、高端化药及特色中药等重点领域发展。拥有几十个在研高端化药，其中近10个已处临床或报产阶段；拥有妇科、儿科、皮肤科等药品批准文号400余个，其中独家特色中西药40多个，独家医保品种20余个。现有数个正处国际临床II期、III期的大分子生物药，是第一家大分子创新生物药在美国进入II期、III期临床试验的中国企业，将带领中国生物药叩响美国的大门。 公司已形成以安徽为主的小分子高端化药、植物药生产中心，以四川为主的皮肤科、妇科生产中心，以辽宁为主的骨科、治疗型大输液生产中心，以北京、上海为主的大分子生物药研发与生产中心及以浙江为主的原料药生产中心。 公司医药业务覆盖除港澳台以外的所有省市区，药品制剂在全国二级以上医院的覆盖率超过60%，同时作为世界较大的维生素B5及维生素原B5生产供应商，公司医用原料药销售网络辐射欧、美等多个国家和地区，全球市场占有率40%-45%，稳居龙头地位。 面向未来，公司将始终专注于医药、医疗健康事业，坚持"整合、创新、国际化"的发展战略，恪守"务实、创新、诚信、勤奋"的核心价值观，致力于为客户创造效益，为员工创造平台，为股东创造财富，为社会创造价值，持续成长为全球医药健康事业的专家。

The company was founded in December 2005, built a variety of plant and GMP workshop, office space, auxiliary housing, with various types of imports and domestic advanced equipment. The company is a professional R&D, production, sales of rapid in vitro diagnostic reagents of the national high-tech enterprises, Zhejiang Province post-doctoral research station and Huzhou City academician expert workstation set up units. At present, the company's products are widely used in Infectious Disease Rapid Test, Drugs of Abuse Test, Pregnancy & Fertility Tumor Marker Cardiac Marker and other fields, with repeatability and specificity, high sensitivity, easy to operate and other technical characteristics. During the outbreak, the company's new coronavirus testing reagents are widely sold to all corners of the globe. It has made outstanding contributions to the fight against the new coronavirus for all mankind. Since its inception, the company to scientific and technological innovation as the driving force for development, committed to the cause of human health, in order to promote high-tech diagnosis and treatment technology, improve the level and quality of human medical services and efforts. At present, the majority of the company's products have been CE certificated. The company now hopes to expand into the European market. Find local partners in Europe. Better service to the European market.

Zhuhai Livzon DiagnosticsInc. (hereinafter referred to as “Livzon Diagnostics”) was established in 1989. It is the first high-tech subsidiary of thelisted company, Livzon Pharmaceutical Group (A-shareand H-share listed company),whospecializing in in-vitro diagnosticsin research, developing, manufacturingand marketing of diagnosis productsand automation equipment.Diagnostic Kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Colloidal Gold)